PETHEMA Foundation: all 106 studies
Page 1 of 2. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingNCT07862946Phase 2
- Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple MyelomaNot yet recruitingNCT07637526
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingNCT07507760Phase 2
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingNCT07478991Phase 3
- Treatment for Ph-negative ALL for Adults up to 65 YearsNot yet recruitingNCT07443592Not applicable
- Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)RecruitingNCT07045909Phase 2
- Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
- Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06544785Phase 2
- Treatment Protocol for Newky Diagnosed Adult Ph Positive ALLNot yet recruitingNCT06175702
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingNCT05558319Phase 3
- Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in AdultsRecruitingNCT04179929Not applicable
- Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug ClassesActive, not recruitingNCT06282978Phase 2
- Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaActive, not recruitingNCT05849610Phase 2
- A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
- Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.Active, not recruitingNCT05527340Phase 2
- Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.Status unknownNCT05297240
- Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTStatus unknownNCT05218603
- Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingNCT05060627Phase 1/2
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsActive, not recruitingNCT04802356Phase 2
- Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
- Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
- Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid LeukemiaCompletedNCT04230239Phase 2
- Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
- Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
- REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
- Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
- SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
- Study of Prognostic Factors in Adult Lymphoblastic LymphomaStatus unknownNCT03571997
- PETHEMA-BLIN-01/PET069014 (BLIN-01)TerminatedNCT03523429Phase 2
- Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03477643
- Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
- Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1
- Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02776605Phase 2
- Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
- Epidemiologic Registry PETHEMA LMA 2015Status unknownNCT02607059
- VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 YearsCompletedNCT02606825
- GEM-CLARIDEX: Ld vs BiRdStatus unknownNCT02575144Phase 3
- CML Treated With Bosutinib After RelapseCompletedNCT02445742Phase 2
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple MyelomaCompletedNCT02406144Phase 3
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
- Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02319135Phase 3
- Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT02036489Phase 4
- Clinical Guidelines for APL TreatmentStatus unknownNCT02020161Phase 4
- Epidemiologic Registry PETHEMA LMA 2013CompletedNCT02006004
- Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years OldCompletedNCT01916252Phase 3
- Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseStatus unknownNCT01802450Phase 2
- Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTSCompletedNCT01540812
- Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
- Treatment of Relapsed or Refractory Acute Myeloblastic LeukemiaCompletedNCT01435343Phase 1/2
- Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 YearsStatus unknownNCT01376427Not applicable
- Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple MyelomaCompletedNCT01376401Phase 2
- Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)Status unknownNCT01366898Phase 4
- PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 YearsStatus unknownNCT01358201Phase 4
- PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
- Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose DexamethasoneCompletedNCT01237249Phase 2
- LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)TerminatedNCT01198054Phase 4
- Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly DiagnosedCompletedNCT01194791Phase 2
- Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 YearsTerminatedNCT01193400Phase 2
- Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical RelapseCompletedNCT01087008Phase 4
- Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal FailureCompletedNCT01084837Phase 2
- LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)CompletedNCT01041040Phase 4
- PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic LeukemiaTerminatedNCT00944008Phase 3
- Treatment of High Risk Adult Acute Lymphoblastic LeukemiaCompletedNCT00853008Phase 4
- Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)CompletedNCT00840346Phase 1/2
- A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSFTerminatedNCT00765050Phase 1/2
- ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)CompletedNCT00662948Phase 2
- Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple MyelomaCompletedNCT00652041Phase 4
- Velcaflagida in Relapsed or Refractary Acute Myeloid LeukemiaCompletedNCT00651781Phase 1/2
- MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative ConditioningCompletedNCT00564200Phase 2
- Pethema Multiple Myeloma 2000CompletedNCT00560053Phase 3
- LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic LeukemiaCompletedNCT00526409Phase 4
- LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia PositiveCompletedNCT00526305Phase 4
- LAL-BR/2001: Study Treatment to Low Risk ALLCompletedNCT00526175Phase 4
- Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)CompletedNCT00504764Phase 4
- SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic SyndromeTerminatedNCT00495547Phase 2
- PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic LeukemiaCompletedNCT00494897Phase 4
- Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00488709Phase 4
- Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic SyndromeCompletedNCT00488436Phase 4
- SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic LeukemiaCompletedNCT00487448Phase 4
- QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of ProgressionCompletedNCT00480363Phase 3
- LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)CompletedNCT00466258Phase 4
- Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)CompletedNCT00465933Phase 4
- Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 YearsCompletedNCT00464217Phase 4
- Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell TransplantationCompletedNCT00462878
- GEM05 for Patients With Multiple Myeloma Under 65 YearsCompletedNCT00461747Phase 3
- GEM05 for Patients With Multiple Myeloma More Than 65 Years OldCompletedNCT00443235Phase 3
- AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic ProgenitorsCompletedNCT00415103Phase 4
- Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)CompletedNCT00408278Phase 4
- VELCADEXA: Velcade and Dexamethasone in Multiple MyelomaCompletedNCT00391157Phase 2
- Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary AspergillosisCompletedNCT00391014Phase 2
- Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid LeukaemiaCompletedNCT00390897Phase 4
- Treatment of Acute Myeloblastic Leukemia in Younger PatientsCompletedNCT00390715
- Glivec in Ph Positive Lymphoblastic LeukemiaCompletedNCT00388895Phase 2